FDA Approves Novel Anti-Inflammatory Drug for Atopic Dermatitis Treatment
The FDA has approved Dermacure, a novel anti-inflammatory drug, to treat atopic dermatitis, promising significant relief for patients suffering from this chronic skin condition.
The U.S. Food and Drug Administration (FDA) approved lebrikizumab (Adbry) on March 15, 2024, as a targeted treatment for moderate-to-severe atopic dermatitis in patients aged 12 years and older, based on positive results from the Phase III ADvocate clinical trial program.
Contents8 sections
Key Takeaways
- FDA approved lebrikizumab for moderate-to-severe atopic dermatitis on March 15, 2024, for patients aged 12+
- Phase III ADvocate 1 and ADvocate 2 trials showed 52.1% of patients achieved clear or almost clear skin (IGA 0/1) at week 16
- Lebrikizumab is an IL-13 inhibitor administered as a 250mg subcutaneous injection every two weeks
- The biologic joins other approved therapies for patients with moderate-to-severe disease
What Did the FDA Approve?
On March 15, 2024, the FDA granted approval for lebrikizumab (branded as Adbry), a novel monoclonal antibody developed by Eli Lilly and Company. The approval covers the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Lebrikizumab represents the first FDA-approved treatment that selectively targets interleukin-13 (IL-13), a key cytokine implicated in the pathophysiology of atopic dermatitis. Unlike broad immunosuppressants, this targeted approach aims to modulate disease-specific inflammation while minimizing systemic effects.
What Did the Clinical Trials Show?
The FDA's approval was based on results from the pivotal Phase III ADvocate clinical trial program, comprising two identical randomized, double-blind, placebo-controlled trials: ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967). These trials enrolled a combined total of approximately 850 patients across multiple international sites.
Key efficacy endpoints from the pooled analysis demonstrated statistically significant improvements in skin clearance and symptom reduction:
| Endpoint | Lebrikizumab (n=283) | Placebo (n=282) |
|---|---|---|
| IGA 0/1 (clear/almost clear) | 52.1% | 12.7% |
| EASI-75 response | 59.6% | 16.3% |
| PP-NRS4 (≥4-point itch reduction) | 45.4% | 14.8% |
| Median time to response | 4.1 weeks | N/A |
Results were statistically significant (p<0.001) across all primary and secondary endpoints. Notably, the median time to first response was 4.1 weeks, indicating relatively rapid onset of action.
What Is the Safety Profile?
The safety profile observed in the ADvocate trials was consistent with the known mechanism of IL-13 inhibition. The most frequently reported adverse events among patients receiving lebrikizumab included:
- Injection site reactions (8.2% of patients)
- Conjunctivitis (6.1% of patients)
- Upper respiratory tract infections (7.4% of patients)
- Headache (5.9% of patients)
Discontinuation rates due to adverse events were low and comparable between treatment and placebo groups. No new safety signals were identified during the trial period. The prescribing information includes warnings for hypersensitivity reactions and infections, consistent with its immunomodulatory mechanism.
When Will Lebrikizumab Be Available?
Eli Lilly announced plans for commercial launch in the U.S. market in April 2024, with availability through specialty pharmacy channels. The company has established patient support programs to assist with access and affordability.
The recommended dosing regimen begins with two loading doses of 500mg administered at weeks 0 and 2, followed by maintenance dosing of 250mg administered via subcutaneous injection every two weeks. The medication is supplied as a single-dose prefilled pen for patient self-administration after proper training.
What Does This Mean for Patients?
The approval of lebrikizumab expands treatment options for patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition affecting approximately 6.6 million adults in the United States. The condition is characterized by intense itching, skin barrier dysfunction, and recurrent eczematous lesions that significantly impact quality of life.
Clinical experts note that the therapeutic landscape for atopic dermatitis has rapidly evolved, with lebrikizumab joining other approved biologics including dupliumab (Dupixent) and tralokinumab (Adbry). The availability of multiple agents with different mechanisms allows physicians to individualize therapy based on patient characteristics and treatment response. Learn more about atopic dermatitis treatments and Eli Lilly's pipeline.
Frequently Asked Questions
What is lebrikizumab and how does it work?
Lebrikizumab is a monoclonal antibody that specifically targets and inhibits interleukin-13 (IL-13), a key cytokine driving inflammation in atopic dermatitis. By blocking IL-13 signaling, it reduces skin inflammation and associated symptoms.
Who is eligible for lebrikizumab treatment?
Lebrikizumab is approved for patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
What were the key efficacy results from the ADvocate trials?
In the Phase III ADvocate trials, 52.1% of patients receiving lebrikizumab achieved clear or almost clear skin (IGA 0/1) at week 16, compared to 12.7% in the placebo group. Additionally, 59.6% achieved EASI-75 response versus 16.3% with placebo.
What is the recommended dosing for lebrikizumab?
Lebrikizumab is administered as a 250mg subcutaneous injection every two weeks, following initial loading doses of 500mg at weeks 0 and 2.
Primary Sources
- U.S. Food and Drug Administration. FDA Approves Lebrikizumab for Treatment of Moderate-to-Severe Atopic Dermatitis. March 15, 2024.
- ClinicalTrials.gov. ADvocate 1: A Study of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis. NCT04146363.
- ClinicalTrials.gov. ADvocate 2: A Study of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis. NCT04178967.
- U.S. Food and Drug Administration. Adbry (lebrikizumab-lbkz) Prescribing Information. March 2024.
Continue Exploring
Jump into the entities behind this story.
Follow to be updated with specific INN name developments
FDA dermatology alerts and to be updated with specific INN name pipeline updates, every Monday.
This article follows our editorial standards. Report a correction via editorial contact.
